Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2024-02-28 Report Publication Anno…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics - Quarterly report Q4 2023
Report Publication Announcement Classification · 100% confidence The document is a short announcement (approx. 2,800 characters) that informs readers about the release of the Q4 2023 financial results. It does not contain the actual financial statements or substantive financial data, but instead provides a link to the company's website to access the report. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). Q4 2023
2024-02-28 English
Nykode Therapeutics – invitation to Q4 2023 financial results presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement (3249 characters) dated February 22, 2024, stating that Nykode Therapeutics will release its Q4 2023 financial results on February 28, 2024, and will host a subsequent webcast presentation. It explicitly mentions that the financial report will be accessible in the 'Financial Reports and Presentations section' of the website. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or availability of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA).
2024-02-22 English
Nykode Therapeutics – invitation to Q4 2023 financial results presentation
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3139 characters) dated February 22, 2024, explicitly stating that Nykode Therapeutics 'will release its fourth quarter 2023 financial results before the opening of financial markets on Wednesday, February 28, 2024.' It then provides details for a subsequent webcast presentation to review those results. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of a report (like Q4 results) and provides details for a presentation/webcast about it, it should be classified as a Report Publication Announcement (RPA). It is not the full financial report (IR) or the earnings release highlights (ER), but the announcement of when those items will be available and presented.
2024-02-22 English
Nykode Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a short announcement (2769 characters) stating that the CEO of Nykode Therapeutics will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, and provides webcast details. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing about dividends, insider trades, or capital changes. It is an announcement about the company's participation in a major industry event, which falls under general investor relations communication. Since there is no specific category for 'Conference Presentation Announcement,' and it is an announcement about future investor engagement rather than the release of a formal report, it best fits the general 'Regulatory Filings' fallback category (RNS) or potentially Investor Presentation (IP) if the content was the presentation itself. However, since it is purely an announcement *of* a presentation, and not the presentation material or a formal regulatory disclosure, RNS is the most appropriate general catch-all for non-standard investor updates, although IP is also plausible if interpreted broadly as investor-facing material. Given the context of providing dates and webcast links for an external conference, RNS is chosen as the most neutral fit for an announcement that doesn't match the specific report types.
2023-12-19 English
Nykode Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Report Publication Announcement Classification · 99% confidence The document is a short announcement (2465 characters) stating that Nykode Therapeutics will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. It provides details about the presentation time, location (virtual access), and includes a link to the webcast and the Investors section of the company's website where the presentation materials can be accessed. This structure—announcing participation in an external event and directing users to where the presentation/materials are located—fits the definition of a Report Publication Announcement (RPA), as it is an announcement about the availability of presentation materials, rather than the presentation itself or a formal regulatory filing like a 10-K or ER. It is not a general regulatory filing (RNS) because it specifically concerns the publication/presentation of investor materials.
2023-12-19 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically mentioning 'Quarterly Report', 'Half-yearly Report', 'Annual Report', and 'Annual General Meeting'. It is not the report itself, but a schedule of when reports/meetings will occur. Since there is no specific category for a 'Financial Calendar', and it is an announcement about future corporate events/filings, the most appropriate classification is the general 'Regulatory Filings' (RNS) as a miscellaneous announcement, or potentially 'RPA' if it were announcing the publication of a specific report, but here it is a forward-looking schedule. Given the nature of providing a schedule of future regulatory/financial events, RNS is the best fit among the provided options, as it is a general regulatory announcement.
2023-12-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.